Literature DB >> 9201971

Human factor IX binds to specific sites on the collagenous domain of collagen IV.

A S Wolberg1, D W Stafford, D A Erie.   

Abstract

The primary region of factor IX that mediates binding to bovine aortic endothelial cells resides in residues 3-11 of the N-terminal region known as the Gla domain. Recently, it was proposed that the observed binding to endothelial cells is actually a measure of the interaction between factor IX and collagen IV (Cheung, W. F., van den Born, J., Kuhn, K., Kjellen, L., Hudson, B. G., and Stafford, D. W. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 11068-11073). To confirm that factor IX binds to collagen IV and to examine the specificity of this interaction, we used scanning force microscopy to examine factor IX binding to collagen IV. We imaged collagen IV in the presence and the absence of factor IX and observed specific interactions between factor IX and collagen IV. Our results demonstrate that factor IX binds to collagen IV at specific sites in the collagenous domain approximately 98 and approximately 50 nm from the C-terminal pepsin-cleaved end.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9201971     DOI: 10.1074/jbc.272.27.16717

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  12 in total

Review 1.  Mapping structural landmarks, ligand binding sites, and missense mutations to the collagen IV heterotrimers predicts major functional domains, novel interactions, and variation in phenotypes in inherited diseases affecting basement membranes.

Authors:  J Des Parkin; James D San Antonio; Vadim Pedchenko; Billy Hudson; Shane T Jensen; Judy Savige
Journal:  Hum Mutat       Date:  2011-02       Impact factor: 4.878

2.  Evidence of clinically significant extravascular stores of factor IX.

Authors:  D Feng; K A Stafford; G J Broze; D W Stafford
Journal:  J Thromb Haemost       Date:  2013-12       Impact factor: 5.824

3.  Adding some muscle to blood coagulation.

Authors:  Dougald M Monroe
Journal:  Blood       Date:  2016-10-06       Impact factor: 22.113

4.  von Willebrand factor binding to myosin assists in coagulation.

Authors:  Veronica H Flood; Tricia L Slobodianuk; Daniel Keesler; Hannah K Lohmeier; Scot Fahs; Liyun Zhang; Pippa Simpson; Robert R Montgomery
Journal:  Blood Adv       Date:  2020-01-14

Review 5.  Animal models of hemophilia.

Authors:  Denise E Sabatino; Timothy C Nichols; Elizabeth Merricks; Dwight A Bellinger; Roland W Herzog; Paul E Monahan
Journal:  Prog Mol Biol Transl Sci       Date:  2012       Impact factor: 3.622

6.  Sensitivity of whole blood clotting time and activated partial thromboplastin time for factor IX: relevance to gene therapy and determination of post-transfusion elimination time of canine factor IX in hemophilia B dogs.

Authors:  T C Nichols; H W G Franck; C T Franck; N De Friess; R A Raymer; E P Merricks
Journal:  J Thromb Haemost       Date:  2012-03       Impact factor: 5.824

Review 7.  Protein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von willebrand disease, and factor VII deficiency.

Authors:  Timothy C Nichols; Aaron M Dillow; Helen W G Franck; Elizabeth P Merricks; Robin A Raymer; Dwight A Bellinger; Valder R Arruda; Katherine A High
Journal:  ILAR J       Date:  2009

8.  Factor IX binding to collagen.

Authors:  D Gailani
Journal:  J Thromb Haemost       Date:  2009-08-19       Impact factor: 5.824

9.  Intraarticular factor IX protein or gene replacement protects against development of hemophilic synovitis in the absence of circulating factor IX.

Authors:  Junjiang Sun; Narine Hakobyan; Leonard A Valentino; Brian L Feldman; R Jude Samulski; Paul E Monahan
Journal:  Blood       Date:  2008-08-20       Impact factor: 22.113

10.  Muscle Gene Therapy for Hemophilia.

Authors:  Denise E Sabatino; Valder R Arruda
Journal:  J Genet Syndr Gene Ther       Date:  2012-05-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.